GMED · Globus Medical, Inc.

Globus Medical delivered a robust start to 2026 with worldwide net sales reaching $759.9 million, reflecting 27% as-reported growth over Q1 2025, including a significant $82.7 million contribution from the Nevro acquisition. Excluding Nevro, base business sales grew 13.2%, highlighting organic momentum in core spine and enabling technologies amid share gains and procedural volume strength. US spine led with three consecutive quarters of 10% growth, complemented by expansion across key segments. GAAP net income surged 64.7% to $124.3 million, with diluted EPS rising 66.6% to $0.90, while non-GAAP EPS climbed 64.7% to $1.12. Management attributes this to disciplined manufacturing, supply chain initiatives, structural cost actions, and operating leverage exceeding sales growth. CFO Kyle Kline noted Nevro's performance aligned with expectations during ongoing integration into Globus' systems. CEO Keith Pfeil emphasized the ecosystem's focus on improved surgical outcomes via closed-loop intelligence. The company reaffirmed full-year revenue guidance at $3.18-$3.22 billion but raised non-GAAP EPS outlook to $4.70-$4.80 from $4.40-$4.50, signaling confidence in sustained earnings expansion and value creation.